CARMOSINO, MONICA
 Distribuzione geografica
Continente #
NA - Nord America 36
EU - Europa 19
AS - Asia 2
Totale 57
Nazione #
US - Stati Uniti d'America 36
IT - Italia 19
VN - Vietnam 2
Totale 57
Città #
Bari 9
Fairfield 6
Statte 6
Ashburn 4
Buffalo 3
Chicago 2
Dong Ket 2
Las Vegas 2
Altamura 1
Dallas 1
Dulles 1
Los Angeles 1
Miami 1
Milan 1
Pasadena 1
Rome 1
Seattle 1
Wilmington 1
Totale 44
Nome #
null, file dd9e0c65-560b-1e9c-e053-3a05fe0a45ef 35
null, file dd9e0c65-4878-1e9c-e053-3a05fe0a45ef 5
Simvastatin increases AQP2 urinary excretion in hypercholesterolemic patients: A pleiotropic effect of interest for patients with impaired AQP2 trafficking., file dd9e0c6a-27b9-1e9c-e053-3a05fe0a45ef 4
Targeting unfolded protein response reverts ER stress and ER Ca2+ homeostasis in cardiomyocytes expressing the pathogenic variant of Lamin A/C R321X, file e134fe5f-7ceb-452d-be62-2228a7da5583 4
Human β3-Adrenoreceptor is Resistant to Agonist-Induced Desensitization in Renal Epithelial Cells, file dd9e0c6a-33a5-1e9c-e053-3a05fe0a45ef 3
Role of Nuclear Lamin A/C in the Regulation of Nav1.5 Channel and Microtubules: Lesson From the Pathogenic Lamin A/C Variant Q517X, file e3bc6a5f-f2a4-4475-a0b4-dc7e8766da28 3
Pro-inflammatory cytokines as emerging molecular determinants in cardiolaminopathies, file 73a6007f-668d-4e8c-a396-b69f21f8a2f3 2
null, file dd9e0c63-6465-1e9c-e053-3a05fe0a45ef 2
B3 Adrenergic Receptor Agonist Mirabegron Increases AQP2 and NKCC2 Urinary Excretion in OAB Patients: A Pleiotropic Effect of Interest for Patients with X-Linked Nephrogenic Diabetes Insipidus, file d0edc66b-6695-49ef-a341-b641083ba871 1
Role of Lamin A/C Gene Mutations in the signaling defects leading to cardiomyopathies, file dd9e0c69-e957-1e9c-e053-3a05fe0a45ef 1
Totale 60
Categoria #
all - tutte 122
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202118 0 0 0 1 5 2 0 3 0 3 0 4
2021/202211 0 0 1 0 1 1 1 0 1 2 3 1
2022/202329 1 3 3 5 2 1 1 1 0 1 3 8
Totale 60